FenBen in Stage 4 tumors

Fenbendazole and cancer https://karger.com/cro/article-pdf/18/1/856/4381509/000546362.pdf Fenbendazole, inexpensive, widely accessible antiparasitic drug used in veterinary medicine Patent expired in the early 1990s, making FBZ available as a generic drug Case 1 An 83-year-old female October 2021 Stage 4 breast cancer Initially diagnosed in 2009 Treated 2009, bilateral mastectomy Recurrence was diagnosed in 2021. Liver biopsy, confirmed metastatic breast Ascitic fluid confirmed metastatic breast carcinoma. Magnetic resonance imaging of the spine, October 2021 metastatic breast cancer, T10, T12, L1, L2, L3, L4, L5, S1, S2, and the iliac bones. A PET/CT scan on December 29, 2021, showed six hypermetabolic lung lesions Largest was 2.8 × 1.5 cm Hypermetabolic liver lesions, 2.9 × 1.7 cm Hypermetabolic bone lesions, notably a 5.0 × 2.9 cm lytic lesion in L4, extending into the spinal canal, etc The patient declined further conventional chemotherapy or radiation therapy and was placed under hospice care. November 22, 2021 Self-administering FBZ daily at a dose of 222 mg. In December 2021, she received fulvestrant injection, (an estrogen receptor blocker) intended to inhibit cancer growth January 2022 Targeted radiation for two painful spinal metastases. These tumors disappeared rapidly, relieving her pain within a few days. Continued taking 222 mg/day of FBZ for 8 months. During this time, her liver enzymes normalized CA 27.29 tumor marker dropped from 316 (November 2021) to 36.6 (July 2022) April 20, 2022, PET scan confirmed the absence of any abnormal metabolic activity indicative of cancer. June 2022 Patient was confirmed to have no evidence of active disease. All treatments were discontinued, and she was considered to be in complete remission. Follow-up monitoring was scheduled every 3–6 months. Throughout her FBZ treatment, she continued her regular supplementation of vitamin D (5,000 IU) and a multivitamin. Subsequent PET scans showed no abnormal metabolic activity. The FBZ treatment period revealed no adverse effects at this dosage. The patient remains recurrence-free and continues to take FBZ daily nearly 3 years after being declared to be in remission. Joe Tipp’s Protocol https://www.fenbendazole.org/fenbendazole-information/fenbendazole-dosage-guide/ Case 2, Prostate cancer, 75 year old man Bone scans and CT scans, metastases in the spine, pelvic bones, and right humeral head Conventional treatments Complementary treatments The use of FBZ coincided with continued regression of metastatic lesions and sustained undetectable PSA levels After 26 months of sustained regression and no new progression, the patient remains in near-complete response and continues FBZ with conventional therapy Case 3, 63-year-old man Hip growth, melanoma. PET-CT showed multiple hypermetabolic foci – peritoneal and retroperitoneal nodules, focal uptake in the stomach and small bowel, lesions in the right gluteus medius, quadratus femoris, and L5 vertebra. Conventional and complementary treatments The patient remains melanoma recurrence-free over 11 months after being declared to be in remission. Case Presentations All three patients, no reported adverse effects Conclusion FBZ demonstrates potential as a novel promising therapeutic option for repurposing in oncology. Its ability to contribute to tumor regression and achieve disease remission warrants further clinical research to establish its efficacy and optimize its use. Learn more about your ad choices. Visit megaphone.fm/adchoices